Articles On Capitol Health (ASX:CAJ)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

  US markets kicked off the post Easter week by giving up ground on what was a winning month for March and a strong first quarter. New inflation data raised concerns that the Fed may struggle to hit its target of three rate cuts by the end...

A compilation of stories relating to the February 2024 corporate reporting season in Australia, including FNArena’s final balance for the season. Content (in chronological order of publication): -Healthcare, REITs, Uranium & Banks-Rudi...

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to good cost control. -Brokers raise targets following Capitol Health’s first half results-The earnings margin increased by 200bps due to...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

  US stocks fell for a second session Tuesday, as steep declines in major tech names such as Apple dragged the broader market further from the record highs recently reached. The Nasdaq Composite pulled back by 1.65 per cent to 15,939.59 as...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AGI)) - Ainsworth Game Technology ((ART)) - Airtasker ((ALX)) - Atlas Arteria ((AFG)) - Australian Finance Group ((CAJ)) - Capitol Health ((CLU)) - Cluey ((DOC)) - Docto...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

FNArena's dedicated ESG Focus news section zooms in on matters Environmental, Social & Governance (ESG) that are increasingly guiding investors preferences and decisions globally. For more news updates, past and future: https://www.fnar...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stocks slid on Thursday as Wall Street parsed commentary from Federal Reserve Chair Jerome Powell while monitoring a key milestone for a closely followed bond yield. Powell noted that inflation was still too high and would likely require lo...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

  Stocks retreated on Wednesday after the Federal Reserve said it would leave interest rates unchanged but indicated another hike on the horizon. The three major indexes closed at session lows. The S&P 500 dropped 0.94 per cent to 4,402...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

In this week's Weekly Insights:-Outlook Negative, With Plenty Of Silver Linings-Conviction Calls & Best IdeasBy Rudi Filapek-Vandyck, EditorOne of the stand-out features of the August results season has been the resilience of household ...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AX1)) - Accent Group ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((ALC)) - Alcidion Group ((ALK)) - Alkane Resources ((APA)) - APA Group ((A1N)) - ARN Media ((AIA)) -...

The Cochlear Limited (ASX: COH) share price bounced dramatically higher this week following a bumper report. But is the Cochlear share price looking a little expensive? Stock Doctor’s Daniel Ortisi weighs in. Hearing solutions provider Coch...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Earnings season has now kicked off and countless ASX shares are getting ready to hand in their report cards. Goldman Sachs has been running the rule over the market and has picked out a number of ASX shares as having potential for positive...

There is no getting around that smaller ASX mining shares can be risky. That’s because junior miners are often involved in exploration and that tends to have a binary outcome — you either find the mineral or you don’t. But if you can manag...

Many of Australia’s top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here’s why the...

If you’re looking for ASX growth shares to buy, then look no further. That’s because Morgans has recently named some among its best ideas for the month of July. Two that make the cut are listed below. Here’s why it is very bullis...

For more than a year now, experts have been saying ASX healthcare shares are the place to park your money. The reasoning is that health is a type of spending that consumers are reluctant to cut back even in times of economic stress.  But l...

Unfortunately for investors, there’s no guarantee that today’s market darlings will remain in favour with investors in the future. When companies go through difficult periods, many investors will sell off their holdings and move onto s...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

While US and Japanese stocks have shot ahead in 2023, the S&P/ASX 200 Index (ASX: XJO) has been left behind. Many experts attribute this to the relatively small presence of the technology sector in the Australian market. The ASX 200 i...

Bega Cheese Ltd (ASX: BGA) shares have continued their decline on Thursday. In morning trade, the diversified food company’s shares have dropped 3% to a new decade-low of $3.02. This means they are now down over 21% since the start of th...

The Bega Cheese Ltd (ASX: BGA) share price was in a world of pain on Wednesday, cascading to its lowest level in almost a decade. Bega’s bitter performance stood out like a sore thumb against a backdrop of the S&P/ASX 200 Index (ASX: X...

The S&P/ASX 200 Index (ASX: XJO) is on form again and on course to record a strong gain. In afternoon trade, the benchmark index is up 1.2% to 7,202.1 points. Four ASX shares that have failed to follow the market higher today are lis...

Invex granted orphan drug designation in Europe Resonance Health has a new CEO EBR to raise $35m as it eyes market launch   Invex Therapeutics (ASX:IXC) announced the granting of orphan drug designation (ODD) from the European Medicines A...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Goldman has Buy recommendations for health imaging stocks Capitol Health and Integral Diagnostics Capitol Health’s earnings multiple is cheap, says Goldman Integral is currently Goldman’s cheapest stock across its coverage   Goldman Sachs...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

If you’re wanting exposure to the healthcare sector, then it could be worth listening to what Goldman Sachs is recommending at this side of the market. It has been looking at the services side of the sector and has picked out two ASX hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

In turbulent times such as now, ASX healthcare shares have typically been in favour. After all, even when high inflation or rising interest rates eat into spending power, consumers still want to take care of their physical and mental well-...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

The efficient market hypothesis says share prices always reflect all available information about the businesses. However, veteran ASX investors would know that in reality that’s not necessarily true. Sometimes the market just fails to full...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

In part one of this note to young investors, I set out the reasons why I think young investors should steer clear of index funds and instead invest in high-quality, growing companies. So, the question is: how to find and invest in these com...

You want your portfolio to perform better than the market, right? If not, then you might as well just buy passive ETFs and be done with it. The whole point of owning a basket of company-specific stocks is because you want better returns t...

ShareCafeS&P500 rises on hopes that the worst of bank crisis is over                    The S&P 500 rose Thursday, as investors bet the worst of the regional bank crisis has passed. Weekly jobless claims increased by 7,000 to...